CSIMarket
 


Genocea Biosciences Inc   (GNCA)
Other Ticker:  
 

Genocea Biosciences Inc 's Working Capital Ratio

GNCA's quarterly Working Capital Ratio and Current Assets, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the first quarter 2022, Working Capital Ratio deteriorated to 1.35 below Genocea Biosciences Inc 's average Working Capital Ratio.

Within Biotechnology & Pharmaceuticals industry 253 other companies have achieved higher Working Capital Ratio than Genocea Biosciences Inc in first quarter 2022. While Working Capital Ratio total ranking in the first quarter 2022 has deteriorated compared to the prior quarter from 2935 to 3715.

Explain Working Capital Ratio
How much in Current Assets GNCA´s has?
What is the value of GNCA´s Current Liabilities?


GNCA Working Capital Ratio (Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
(Jun 30 2021)
II. Quarter
(Mar 31 2021)
I. Quarter
Y / Y Current Liabilities Change 57.83 % -25.25 % -38.26 % -31.09 % -22.1 %
Y / Y Current Assets Change -64.53 % -49.14 % -43.97 % 155.05 % 136.73 %
Working Capital Ratio MRQ 1.35 2.24 3.44 4.24 6.02
GNCA's Total Ranking # 3715 # 2935 # 578 # 183 # 1615
Seq. Current Liabilities Change -3.5 % 27.06 % -0.86 % 29.83 % -54.29 %
Seq. Current Assets Change -41.64 % -17.37 % -19.55 % -8.58 % -16.3 %



Working Capital Ratio first quarter 2022 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 254
Healthcare Sector # 995
Overall Market # 3715


Working Capital Ratio Statistics
High Average Low
78.31 13.6 1.15
(Jun 30 2016)   (Jun 30 2020)




Financial Statements
Genocea Biosciences Inc 's Current Liabilities $ 18 Millions Visit GNCA's Balance sheet
Genocea Biosciences Inc 's Current Assets $ 24 Millions Visit GNCA's Balance sheet
Source of GNCA's Sales Visit GNCA's Sales by Geography


Cumulative Genocea Biosciences Inc 's Working Capital Ratio

GNCA's Working Capital Ratio for the trailling 12 Months

GNCA Working Capital Ratio

(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
(Jun 30 2021)
II. Quarter
(Mar 31 2021)
I. Quarter
Y / Y Current Liabilities TTM Growth 57.83 % -25.25 % -38.26 % -31.09 % -22.1 %
Y / Y Current Assets TTM Growth -64.53 % -49.14 % -43.97 % 155.05 % 136.73 %
Working Capital Ratio TTM 2.71 3.76 4.01 4.05 3.25
Total Ranking TTM # 2165 # 1646 # 1249 # 1163 # 1432
Seq. Current Liabilities TTM Growth -3.5 % 27.06 % -0.86 % 29.83 % -54.29 %
Seq. Current Assets TTM Growth -41.64 % -17.37 % -19.55 % -8.58 % -16.3 %


On the trailing twelve months basis Due to decrease in Current Liabilities in the I Quarter 2022 to $18.03 millions, cumulative Working Capital Ratio decreased to 2.71 below the Genocea Biosciences Inc average Working Capital Ratio.
Working Capital Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 195 other companies have achieved higher Working Capital Ratio than Genocea Biosciences Inc . While Working Capital Ratio total ranking has deteriorated compared to the previous twelve months ending in the forth quarter 2021 from 1056 to 3783.

Explain Working Capital Ratio
How much in Current Assets GNCA´s has?
What is the value of GNCA´s Current Liabilities?

TTM Working Capital Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 196
Healthcare Sector # 1242
Within the Market # 3715


trailing twelve months Working Capital Ratio Statistics
High Average Low
13.47 4.37 2.32
(Dec 31 2016)   (Dec 31 2017)




Companies with similar Working Capital Ratio in the quarter ending Mar 31 2022, within Biotechnology & Pharmaceuticals Industry Working Capital RatioMar 31 2022 MRQ Current AssetsMar 31 2022 MRQ Current Liabilities
Vir Biotechnology Inc   3.66 $ 2,567.548  Millions$ 702.361  Millions
Erytech Pharma S a   3.65 $ 47.750  Millions$ 13.079  Millions
Adaptive Biotechnologies Corporation  3.64 $ 419.120  Millions$ 115.066  Millions
Bio techne Corp  3.55 $ 593.108  Millions$ 166.838  Millions
Gamida Cell Ltd   3.55 $ 72.712  Millions$ 20.478  Millions
Polarityte Inc   3.45 $ 24.271  Millions$ 7.045  Millions
Innate Pharma Sa  3.38 $ 156.611  Millions$ 46.299  Millions
Coherus Biosciences inc   3.33 $ 512.443  Millions$ 153.748  Millions
Lineage Cell Therapeutics Inc   3.33 $ 81.872  Millions$ 24.593  Millions
Greenlight Biosciences Holdings Pbc  3.28 $ 96.948  Millions$ 29.524  Millions
Apeiron Capital Investment Corp   3.27 $ 0.871  Millions$ 0.267  Millions
Atara Biotherapeutics Inc   3.10 $ 314.389  Millions$ 101.562  Millions
Logicbio Therapeutics Inc   2.96 $ 45.216  Millions$ 15.254  Millions
Denali Therapeutics Inc   2.90 $ 988.436  Millions$ 341.240  Millions
Sangamo Therapeutics Inc   2.87 $ 340.065  Millions$ 118.526  Millions
Aerie Pharmaceuticals Inc   2.75 $ 316.966  Millions$ 115.291  Millions
Applied Genetic Technologies Corporation  2.73 $ 70.527  Millions$ 25.809  Millions
Biocardia Inc  2.72 $ 10.661  Millions$ 3.913  Millions
Calidi Biotherapeutics Inc   2.67 $ 1.033  Millions$ 0.387  Millions
Brainstorm Cell Therapeutics inc   2.61 $ 19.260  Millions$ 7.372  Millions
10x Capital Venture Acquisition Corp Iii  2.56 $ 0.892  Millions$ 0.348  Millions
Cellectis S a   2.54 $ 122.043  Millions$ 48.131  Millions
Zivo Bioscience Inc   2.53 $ 7.486  Millions$ 2.960  Millions
Gilead Sciences Inc   2.47 $ 12,629.000  Millions$ 5,108.000  Millions
Repligen Corp  2.28 $ 944.789  Millions$ 414.451  Millions
Zura Bio Limited  2.27 $ 0.837  Millions$ 0.369  Millions
Taysha Gene Therapies Inc   2.20 $ 106.891  Millions$ 48.617  Millions
Eloxx Pharmaceuticals Inc   2.20 $ 42.147  Millions$ 19.174  Millions
Freeline Therapeutics Holdings Plc  2.18 $ 67.627  Millions$ 30.966  Millions
Meiragtx Holdings Plc  2.18 $ 142.925  Millions$ 65.501  Millions

Date modified: 2023-03-25T04:00:08+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com